In a return to our popular event during the last JP Morgan, Endpoints Editor John Carroll will sit down with Catalent CEO John Chiminski to talk about the year ahead, offering their projections for what 2021 holds in store for the biopharma industry. We’re told Chiminski will be wearing his lucky boots.
Under President Trump the industry was offered a series of executive orders designed to bring European and US prices in line, with the promise for price cuts for Americans. Newly elected President Joe Biden has suggested adopting a new approach modeled along Germany’s get-tough negotiations that tie prices to the medical value they offer patients — as determined by government negotiators. So we’re in for a brand new round of discussions in Washington DC that will have a major impact on the fate of biopharma companies. Don’t miss it.
During 2020 we saw a burst of new deals as various players began to collaborate on new drugs and vaccines for Covid-19. The mRNA field arrived on the commercial playing field with a bang, promising to reshape the multibillion-dollar vaccine industry. And dealmakers of all shapes and sizes switched over to Zoom and found a new, and often far more efficient, way to do deals at a time money has been pouring into R&D organizations promising to revolutionize treatments for all diseases. That’s the setting, so how will that all play out in the year ahead? Let's talk terms.
Following the burst of PD-(L)1 drugs from Merck, Bristol Myers and others, we’re seeing the next big wave of ADCs, cell therapy 2.0, combos and cocktails take shape — possibly even the first truly commoditized checkpoints as well. How is this market going to shape up for the leaders in what has been the fastest growing segment of R&D for the past decade? And how will the pandemic influence the work? We’re calling in the experts.
The booming gene therapy field has underscored the opportunities for new treatments, and all the limitations we’ve been seeing over 2020 among the pioneers in the field. What are the key technical issues involved in AAV and lentiviral work, and who’s setting the pace on payload and durability? Will first-to-market status offer big advantages, or limited markets as patients wait for the best-in-market players out there?